J Korean Breast Cancer Soc.  2003 Sep;6(3):196-200. 10.4048/jkbcs.2003.6.3.196.

Two Cases of Endometrial Carcinoma in Tamoxifen-treated Breast Cancer Patients in Korea

Affiliations
  • 1Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. wcpark@catholic.ac.kr

Abstract

Tamoxifen, the representative of selective estrogen receptor modulaor (SERM), has been widely used not only for the treatment of breast cancer, but also for the prevention of the disease. It is well known that some serious side-effects can infrequently occur with long-term use of tamoxifen and endometrial cancer is one of that disasters. According to NSABP B-14 data, the incidence of endometrial cancer among tamoxifen users was 0.16% and the relative risk was increased by 7.2 fold. In Korea, tamoxifen has been also used as primary endocrine therapy for the treatment of many patients with breast cancer. However, there was no formal report about the endometrial carcinoma occurred subsequently after tamoxifen administration so far. Recently, we experienced two cases of endometrial carcinoma occurred after tamoxifen treatment in breast cancer patients in Korea, and report these cases for reminding breast physicians or patients not to ignore this rare, but serious side effect of tamoxifen.

Keyword

Tamxoifen; Endometrial carcinoma

MeSH Terms

Breast Neoplasms*
Breast*
Disasters
Endometrial Neoplasms*
Estrogens
Female
Humans
Incidence
Korea*
Tamoxifen
Estrogens
Tamoxifen

Cited by  1 articles

Toremifene as an Adjuvant Hormone Therapy for Estrogen Receptor Positive early Breast Cancer: Therapeutic Efficacy and Effect on Endometrium
Heon-Kyun Ha, Wonshik Han, Eunyoung Ko, So Young Kang, Jong Won Lee, Jihyoung Cho, So-Youn Jung, Eun-Kyu Kim, Seung Keun Oh, Yeo-Kyu Youn, Dong-Young Noh
J Breast Cancer. 2007;10(4):258-262.    doi: 10.4048/jbc.2007.10.4.258.

Full Text Links
  • JKBCS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr